Achilles Therapeutics plc American Depositary Shares - ACHL STOCK NEWS

Achilles Therapeutics (ACHL) reported significant progress in Q2 2021, presenting data at AACR and ASCO that demonstrates the ability to quantify active T cell components. The company closed a successful IPO, raising $175.5 million, enhancing its cash reserves to $299.3 million. R&D expenses rose to $10.8 million due to clinical trial activities. The net loss increased to $16.2 million, partly due to the higher share count post-IPO. Achilles is on track to share data from ten patients in the CHIRON and THETIS trials in Q4 2021, with plans to initiate higher dose patient enrollment soon.

Achilles Therapeutics plc (NASDAQ: ACHL) announced the enrollment of the first US patient in its CHIRON clinical trial for treating advanced non-small cell lung cancer (NSCLC) with precision T cell therapy. The trial, which has opened at 10 sites across the UK, EU, and US, aims to enroll up to 40 patients to assess the safety and efficacy of its clonal neoantigen T cell (cNeT) therapy. The CEO expressed optimism about the potential of their innovative approach targeting patient-specific neoantigens. Updates from 10 patients are expected in Q4 2021.

Achilles Therapeutics (NASDAQ: ACHL) presented a poster at the ASCO Annual Meeting 2021 regarding its ongoing phase I/IIa CHIRON trial, which evaluates clonal neoantigen T cells in advanced non-small cell lung cancer (NSCLC). The trial's primary objective is to assess the safety and tolerability of cNeT as a monotherapy and in combination with pembrolizumab, while secondary measures include clinical efficacy. Nearly 75% of NSCLC patients face metastatic disease, highlighting the necessity for innovative treatments like cNeT.

Achilles Therapeutics (NASDAQ: ACHL) reported key developments in its CHIRON and THETIS trials, receiving a go-ahead from the Independent Data Safety Monitoring Committee. The company completed an IPO, raising $175.5 million, with cash reserves expected to fund operations through late 2023. Initial clinical data from six patients indicated stable disease in four and tumor reduction in one. The operating expenses for Q1 2021 were $13.7 million, with a net loss of $13.8 million. Upcoming events include participation in the BofA Securities Healthcare Conference and presentation at the ASCO Annual Meeting.

Achilles Therapeutics plc (NASDAQ: ACHL) is part of a consortium awarded a €3 million ($3.6 million) grant from Horizon 2020, aimed at developing a tool to predict neoantigen immunogenicity. Led by UCL and including notable institutions like The Francis Crick Institute and the Weizmann Institute of Science, the project named DECOD-Ag will enhance cancer immunotherapy, aiming for personalized treatment strategies. Achilles will receive approximately €0.8 million ($1 million) from this funding, validating its expertise in neoantigen prediction algorithms.

Achilles Therapeutics (NASDAQ: ACHL), a clinical-stage biopharmaceutical company, announced its CEO Iraj Ali will participate in a fireside chat at the BofA Securities 2021 Virtual Healthcare Conference on May 13, 2021, at 9:30 a.m. ET. This event highlights the company's work in developing precision T cell therapies targeting clonal neoantigens for treating solid tumors, with ongoing trials for non-small cell lung cancer and melanoma. A webcast of the presentation will be available on their website.

Achilles Therapeutics (NASDAQ: ACHL) announces the appointment of Julie O’Neill as a Non-Executive Director and Markwin Velders, Ph.D. to its Scientific Advisory Board. O’Neill brings over 20 years of experience from companies like Alexion Pharmaceuticals and Gilead Sciences, emphasizing the importance of operations as the firm expands manufacturing capacity. Dr. Velders has significant experience in cell therapy, previously at Kite Pharma. Additionally, Rogier Rooswinkel will resign from the Board before the annual general meeting on June 28, 2021.

Achilles Therapeutics (NASDAQ: ACHL) presented a patient case study from its Phase I/IIa THETIS trial for metastatic melanoma at the AACR Annual Meeting 2021. The study highlighted insights into clonal neoantigen T cells (cNeT) post-dosing. The data demonstrated a significant polyclonal response, indicating the potential for a reproducible potency assay. The case involved a patient who received an immunotherapy combination halted due to toxicity, showing 53% of T cells in the manufactured product were reactive to their clonal neoantigens. Achilles focuses on precision T cell therapies targeted at unique cancer markers.

Achilles Therapeutics (NASDAQ: ACHL) has successfully completed its IPO, raising approximately $175.5 million by offering 9,750,000 American Depositary Shares at $18.00 each. This event marks a significant step for the company as it develops precision T cell therapies targeting clonal neoantigens for treating solid tumors. The offering was managed by major financial institutions including J.P. Morgan and BofA Securities. Proceeds are expected to support ongoing clinical trials.